Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL (ICBMT 2026) - Oct 8, 2026 - Abstract #PL01-1; Pres time: Sep 17, 2026; 10:30 AM - 11:10 AM; Location: Room A(1F); "Our discussion will review the evolution of CD19-directed CAR T-cell therapy from the first pediatric treatment in 2012 to regulatory approval of tisagenlecleucel and its integration into clinical practice...Although these treatments can produce remarkable and potentially curative outcomes, their broader impact remains limited by high costs, complex manufacturing, reimbursement uncertainty, and prolonged treatment timelines. Improving access will require more efficient manufacturing, innovative regulatory and clinical-trial pathways, and new delivery models that connect specialized centers with broader networks of care."
CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Pediatrics • Sickle Cell Disease
|